Aimmune Therapeutics Inc. (NASDAQ:AIMT) shares dropped 2.5% during mid-day trading on Thursday . The stock traded as low as $14.06 and last traded at $14.44, with a volume of 123,276 shares. The stock had previously closed at $14.81.

AIMT has been the subject of several research analyst reports. Zacks Investment Research upgraded Aimmune Therapeutics from a “hold” rating to a “buy” rating and set a $16.00 price objective for the company in a research report on Friday, May 20th. Bank of America Corp. reiterated a “buy” rating on shares of Aimmune Therapeutics in a research report on Monday, May 16th. Wedbush reiterated a “buy” rating and issued a $42.00 price objective on shares of Aimmune Therapeutics in a research report on Wednesday. Credit Suisse Group AG reiterated a “buy” rating and issued a $35.00 price objective on shares of Aimmune Therapeutics in a research report on Friday, August 19th. Finally, Piper Jaffray Cos. reiterated an “overweight” rating and issued a $38.00 price objective on shares of Aimmune Therapeutics in a research report on Wednesday, June 29th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Aimmune Therapeutics has a consensus rating of “Buy” and an average price target of $33.40.

The company’s market capitalization is $620.71 million. The company has a 50 day moving average price of $12.45 and a 200-day moving average price of $13.78.

Aimmune Therapeutics (NASDAQ:AIMT) last announced its earnings results on Wednesday, August 10th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by $0.01. On average, equities analysts expect that Aimmune Therapeutics Inc. will post ($1.71) earnings per share for the current year.

In related news, major shareholder Foresite Capital Fund Ii, L.P. sold 240,000 shares of the company’s stock in a transaction on Tuesday, May 31st. The stock was sold at an average price of $15.23, for a total transaction of $3,655,200.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

An institutional investor recently raised its position in Aimmune Therapeutics stock. RS Investment Management Co. LLC raised its stake in shares of Aimmune Therapeutics Inc. (NASDAQ:AIMT) by 12.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 804,143 shares of the company’s stock after buying an additional 88,180 shares during the period. RS Investment Management Co. LLC owned about 1.90% of Aimmune Therapeutics worth $14,836,000 as of its most recent SEC filing.

Aimmune Therapeutics Inc, formerly Allergen Research Corporation, is a United States-based clinical-stage biopharmaceutical company. The Company focuses on therapeutic approach, including the development of proprietary candidates, for the treatment of peanut and other food allergies. The Company’s Characterized Oral Desensitization Immunotherapy (CODIT) is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.